trabedersen   Click here for help

GtoPdb Ligand ID: 14719

Synonyms: AP-12009 | OT-101
Immunopharmacology Ligand
Compound class: Nucleic acid
Comment: Trabedersen (OT-101) is an 18-mer phosphorothioate antisense oligonucleotide (ASO) that targets transforming growth factor-beta 2 (TGF-β2) mRNA to reduce receptor synthesis. This mechanism is intended for application in cancer therapy.
2D Structure
Click here for help
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CN(C2CC(C(COP(=S)(O)OC3CC(N4C=C(C)C(=O)NC4=O)OC3COP(=S)(O)OC5CC(N6C=C(C)C(=O)NC6=O)OC5COP(=S)(O)OC7CC(N8C=NC9=C8N=CN=C9N)OC7COP(=S)(O)OC%10CC(N%11C=C(C)C(=O)NC%11=O)OC%10COP(=S)(O)OC%12CC(N%13C=CC(=NC%13=O)N)OC%12COP(=S)(O)OC%14CC(N%15C=C(C)C(=O)NC%15=O)OC%14COP(=S)(O)OC%16CC(N%17C=NC%18=C%17N=C(N)NC%18=O)OC%16COP(=S)(O)OC%19CC(N%20C=C(C)C(=O)NC%20=O)OC%19COP(=S)(O)OC%21CC(N%22C=NC%23=C%22N=CN=C%23N)OC%21COP(=S)(O)OC%24CC(N%25C=CC(=NC%25=O)N)OC%24COP(=S)(O)OC%26CC(N%27C=NC%28=C%27N=C(N)NC%28=O)OC%26COP(=S)(O)OC%29CC(N%30C=NC%31=C%30N=C(N)NC%31=O)OC%29COP(=S)(O)OC%32CC(N%33C=CC(=NC%33=O)N)OC%32CO)O2)O)C(=O)NC1=O
Isomeric SMILES CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC%10CC(OC%10COP(=S)(O)OC%11CC(OC%11COP(=S)(O)OC%12CC(OC%12COP(=S)(O)OC%13CC(OC%13COP(=S)(O)OC%14CC(OC%14COP(=S)(O)OC%15CC(OC%15CO)N%16C=CC(=NC%16=O)N)N%17C=NC%18=C%17N=C(NC%18=O)N)N%19C=NC%20=C%19N=C(NC%20=O)N)N%21C=CC(=NC%21=O)N)N%22C=NC%23=C(N=CN=C%23%22)N)N%24C=C(C(=O)NC%24=O)C)N%25C=NC%26=C%25N=C(NC%26=O)N)N%27C=C(C(=O)NC%27=O)C)N%28C=CC(=NC%28=O)N)N%29C=C(C(=O)NC%29=O)C)N%30C=NC%31=C(N=CN=C%31%30)N)N%32C=C(C(=O)NC%32=O)C)N%33C=C(C(=O)NC%33=O)C)O
InChI InChI=1S/C137H175N46O73P13S13/c1-54-27-173(132(198)164-117(54)186)91-13-60(185)75(231-91)34-217-257(204,270)247-64-17-95(174-28-55(2)118(187)165-133(174)199)234-78(64)37-222-262(209,275)249-66-19-97(176-30-57(4)120(189)167-135(176)201)236-80(66)39-223-267(214,280)253-70-23-101(180-50-151-106-111(142)147-48-149-113(106)180)240-84(70)43-227-263(210,276)250-67-20-98(177-31-58(5)121(190)168-136(177)202)235-79(67)38-221-259(206,272)245-62-15-93(171-11-8-89(139)156-130(171)196)232-76(62)35-219-261(208,274)248-65-18-96(175-29-56(3)119(188)166-134(175)200)238-82(65)41-225-268(215,281)255-73-26-104(183-53-154-109-116(183)160-128(145)163-125(109)194)242-86(73)45-228-264(211,277)251-68-21-99(178-32-59(6)122(191)169-137(178)203)237-81(68)40-224-266(213,279)252-69-22-100(179-49-150-105-110(141)146-47-148-112(105)179)239-83(69)42-226-260(207,273)246-63-16-94(172-12-9-90(140)157-131(172)197)233-77(63)36-220-265(212,278)254-72-25-103(182-52-153-108-115(182)159-127(144)162-124(108)193)243-87(72)46-229-269(216,282)256-71-24-102(181-51-152-107-114(181)158-126(143)161-123(107)192)241-85(71)44-218-258(205,271)244-61-14-92(230-74(61)33-184)170-10-7-88(138)155-129(170)195/h7-12,27-32,47-53,60-87,91-104,184-185H,13-26,33-46H2,1-6H3,(H,204,270)(H,205,271)(H,206,272)(H,207,273)(H,208,274)(H,209,275)(H,210,276)(H,211,277)(H,212,278)(H,213,279)(H,214,280)(H,215,281)(H,216,282)(H2,138,155,195)(H2,139,156,196)(H2,140,157,197)(H2,141,146,148)(H2,142,147,149)(H,164,186,198)(H,165,187,199)(H,166,188,200)(H,167,189,201)(H,168,190,202)(H,169,191,203)(H3,143,158,161,192)(H3,144,159,162,193)(H3,145,160,163,194)
InChI Key UFBHAMYSAXCKRQ-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. FDA. 
Search Orphan Drug Designations and Approvals.
Accessed on 06/10/2026. Modified on 06/10/2026. https://www.accessdata.fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm